Search bioRxiv⌕ Search

bioRxiv · 10.1101/2021.06.17.448913

LmbU directly regulates SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780, which are located outside the lmb cluster and inhibit lincomycin biosynthesis in Streptomyces lincolnensis

Abstract

The productions of antibiotics are usually regulated by cluster-situated regulators (CSRs), which can directly regulate the genes within the corresponding biosynthetic gene cluster (BGC). However, few studies have looked into the regulation of CSRs on the targets outside the BGC. Here, we screened the targets of LmbU in the whole genome of S. lincolnensis, and found 14 candidate targets, among of which, 8 targets can bind to LmbU by EMSAs. Reporter assays in vivo revealed that LmbU repressed transcription of SLINC_RS02575 and SLINC_RS05540, while activated transcription of SLINC_RS42780. In addition, disruptions of SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780 promoted the production of lincomycin, and qRT-PCR showed that SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780 inhibited transcription of the lmb genes, indicating that all the three regulators can negatively regulate lincomycin biosynthesis. Whats more, the homologues of LmbU and its targets SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780 are widely found in actinomycetes, while the distributions of DNA-binding sites (DBS) of LmbU are diverse, indicating the regulatory mechanisms of LmbU homologues in various strains are different and complicated. IMPORTANCELincomycin is widely used in clinic treatment and animal husbandry. Our previous study firstly demonstrated that LmbU, a novel transcriptional regulator family, functions as a CSR and positively regulates lincomycin biosynthesis. Here, we revealed that LmbU may act as a pleiotropic transcriptional regulator, and directly regulates SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780 which are located outside the lmb cluster and negatively regulate lincomycin biosynthesis. Interestingly, the homologues of LmbU and its targets are widely found in actinomycetes, indicating the regulatory patterns of LmbU to the targets may exist in a variety of strains. Collectively, our findings elucidated the molecular mechanism with which LmbU regulates the target genes outside the lmb culster, and draw a network diagram of LmbU regulation on lincomycin biosynthesis. This lays a solid foundation for the realization of high-yield of lincomycin in industry, and provides the theoretical basis for the functional research of LmbU family proteins.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Hou, B., Zhang, X., Mao, Y., Wang, R., Ye, J., Wu, H., Zhang, H.. 2021-06-18. LmbU directly regulates SLINC_RS02575, SLINC_RS05540 and SLINC_RS42780, which are located outside the lmb cluster and inhibit lincomycin biosynthesis in Streptomyces lincolnensis. https://doi.org/10.1101/2021.06.17.448913

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

AGPAT2 Inflammatory Metabolic Reprogramming Mediates Immune Checkpoint Inhibitor-associated Myocarditis via LPAR5-pyroptosis Axis

Objectives: Immune checkpoint inhibitors (ICIs), especially programmed cell death protein-1 (PD1) inhibitors, are effective onco-therapeutic agents. However, ICI-associated myocarditis (ICIAM) greatly limits their clinical utility. Imbalance between 1-acylglycerol-3-phosphate O-acyltransferases (AGPAT2) and lysophosphatidic acid (LPA) induced by inflammatory metabolic reprogramming (IMRP) might cause cardiovascular injury. This study aims to explore the link between AGPAT2 pathway and ICIAM as well as identifies diagnosis and treatment targets of ICIAM. Methods: ICIAM model was established by injecting anti-PD1 (PD1) in wild-type (WT) and AGPAT2 heterozygous knockout (AGPAT2+/-) mice. The pathogenic and regulating mechanisms of AGPAT2-LPA and its downstream signaling were examined in vitro and in vivo. A tumor-patient cohort was enrolled to observe the association between serum LPA and risk of ICIAM. Results: In the PD1-induced ICIAM model, myocardial IMRP occurred due to upstream immunity disorder, leading to downstream AGPAT2 degradation via lysosomal pathway and subsequent LPA accumulation. Knockout of AGPAT2 gene also promoted LPA accumulation. The accumulated LPA, by binding to its dominant receptor subtype 5 (LPAR5), triggered pyroptotic myocardial damage and resultant ICIAM. LPAR5 knockdown with siRNA or inhibition with TCLPA5-4 played the most significant rescue effect on myocardial pyroptosis, while stimulating LPAR5 with overdose LPA significantly increased myocardial pyroptosis. In ICI-treated patients, elevated serum LPA was associated with increased risk of ICIAM. Conclusions: IMRP-triggered dysfunction of AGPAT2-LPA-LPAR5-pyroptosis axis is involved in pathogenesis of ICIAM. Several elements in this axis may be the promising targets in diagnosis (LPA as a biomarker) and treatment (LPA or LPAR5 as therapeutics) of ICIAM.

molecular biology↗

Accessibility-guided targeting of NRF2-responsive long noncoding RNA NMRAL2P alters a distinct gene expression program and reduces non-small cell lung cancer proliferation

Aberrant activation of the antioxidant transcription factor NRF2 promotes non-small cell lung cancer (NSCLC) survival and therapy resistance, but downstream effectors beyond redox regulation remain incompletely defined. Transcriptome profiling of lung and NSCLC cells identified the pseudogene-derived long noncoding RNA LOC344887/NMRAL2P as consistently associated with NRF2 activity. The NMRAL2P locus produces three predominant, nuclear-localized isoforms whose expression depends on NRF2 across normal lung, lung adenocarcinoma, and lung squamous carcinoma cells. In-cell SHAPE-MaP identified accessible regions within NMRAL2P transcripts, guiding antisense gapmer design. NMRAL2P depletion inhibited NSCLC cell proliferation and increased sensitivity to cisplatin. Transcriptome analysis revealed that NMRAL2P depletion altered a restricted gene expression program involving cell adhesion and MAPK signaling, with responses distinct from those observed following NRF2 depletion. Core NRF2 antioxidant target genes were largely unaffected by NMRAL2P depletion. These findings support a model in which NRF2 induces NMRAL2P to sustain a distinct gene expression program that contributes to NSCLC proliferation and survival. NMRAL2P represents an RNA effector downstream of NRF2 that links oncogenic NRF2 activity to cellular functions beyond canonical antioxidant responses, providing a potential point of intervention in NRF2-active lung cancers and motivating further investigation of the mechanisms connecting this nuclear RNA to signaling pathways.

molecular biology↗

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

molecular biology↗